

Zambia Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia						
2. Grant number: 1821-ZMB-12a-X; 12-ZMB-08a-Y						
3. Date of Decision Letter: 22 December 2017						
4. Date of the Partnership Framework Agreement: 22 October 2014						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 4 dose(s) per vial , LIQUID						
8. Programme duration¹: 2012 - 2021						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)						
	2012-2017	2018	2019	2020	2021	Total ²
Programme Budget (US\$)	US\$ 35,917,753 ³	US\$ 7,256,000	US\$ 7,422,000	US\$ 7,740,000	US\$ 7,939,000	US\$ 66,274,753
10. Vaccine introduction grant (in US\$) / Product switch grant: Vaccine introduction grant of US\$207,000 disbursed on 30 January 2012 and US\$ 344,500 on 17 December 2012. Return of unused funds of US\$14,232 on 04 February 2016. Country qualifies for a product switch grant of up to US\$ 205,000 to support the PCV switch. The funding will be transferred upon submission and Gavi's approval of the budget for utilisation of the product switch grant.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2012-2017		2018			
Number of Pneumococcal vaccines doses			2,142,800			
Annual Amounts (US\$)	US\$35,917,753 ⁵		US\$7,256,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

13. Self-procurement: Not applicable				
14. Co-financing obligations: Reference code: 1821-ZMB-12a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	374,000	430,400	509,200	619,200
Number of AD syringes	372,400	427,000	504,700	614,400
Number of safety boxes	4,100	4,725	5,575	6,775
Value of vaccine doses (US\$)	US\$1,139,977			
Total co-financing payments (US\$) (including freight)	US\$1,164,000	US\$1,340,000	US\$1,584,500	US\$1,927,500
15. Operational support for campaigns: Not applicable				
16. Additional reporting requirements:				
Reports and other information			Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.			May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.			To be agreed with Secretariat	
17. Financial clarifications: Not applicable				
18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.				

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017